These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 23937190)
1. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Martin-Liberal J; Judson I Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190 [TBL] [Abstract][Full Text] [Related]
2. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt? Le Cesne A Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726 [TBL] [Abstract][Full Text] [Related]
4. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331 [TBL] [Abstract][Full Text] [Related]
5. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Le Cesne A; Reichardt P Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310 [TBL] [Abstract][Full Text] [Related]
6. Trabectedin in soft tissue sarcomas. Petek BJ; Loggers ET; Pollack SM; Jones RL Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274 [TBL] [Abstract][Full Text] [Related]
7. Going further in the knowledge of Yondelis®; what's new in daily clinical practice? Blay JY Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044 [TBL] [Abstract][Full Text] [Related]
8. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects. Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575 [No Abstract] [Full Text] [Related]
9. Trabectedin: Supportive care strategies and safety profile. Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682 [TBL] [Abstract][Full Text] [Related]
11. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer]. Gennigens C; Jerusalem G Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081 [TBL] [Abstract][Full Text] [Related]
13. Trabectedin for the treatment of soft tissue sarcomas. De Sanctis R; Marrari A; Santoro A Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277 [TBL] [Abstract][Full Text] [Related]
14. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Carter NJ; Keam SJ Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287 [TBL] [Abstract][Full Text] [Related]
15. Trabectedin's contribution to the treatment of sarcomas. Blay JY Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729 [TBL] [Abstract][Full Text] [Related]